Agios Pharmaceuticals continues to make remarkable strides in developing new treatments for rare blood disorders. The company’s latest quarterly report for Q2 2024 showcases impressive progress for several diseases:

▪️ Thalassemia: Positive Phase 3 ENERGIZE and ENERGIZE-T study results for mitapivat in all thalassemia subtypes

▪️ PK Deficiency: Promising topline data from Phase 3 ACTIVATE-KidsT study – first safety and efficacy data in children

▪️ Sickle Cell Disease: Nearing completion of enrollment in Phase 3 RISE UP study for mitapivat

Key milestones for 2024:

▪️ File sNDA for mitapivat in thalassemia by End of Year.

▪️ Complete enrollment for sickle cell disease Phase 3 study

▪️ Potential PYRUKYND® launches in thalassemia and sickle cell disease

At OxyDial, we’re inspired by Agios’ commitment to treating rare blood disorders. Their work on mitapivat across multiple indications shows dedication to improving patients’ lives. We applaud their efforts to advance treatment options for thalassemia, PK deficiency, and sickle cell disease.

Read more: https://synapse.patsnap.com/article/agios-shares-q2-2024-results-and-business-highlights

#AgiosPharma #RareBloodDisorders #Thalassemia #PKDeficiency #SickleCellDisease #ClinicalTrials